Halozyme Therapeutics | HALO - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amarin USD 143.56M 12.5M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Baxter International USD 2.15B 133M 2026-06
Cara Therapeutics USD 19.85M 883K 2026-03
Cytokinetics USD 255.27M 125.43M 2026-06
DBV Technologies USD 174.9M 54.3M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Intrexon USD 9.34M 1.77M 2024-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
MannKind USD 52.93M 95K 2026-06
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Pfizer USD 976M 727M 2026-06
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
United Therapeutics USD 1.8B 523.5M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12